Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses
ABPA-MR
1 other identifier
interventional
25
1 country
1
Brief Summary
The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2017
CompletedFirst Posted
Study publicly available on registry
August 29, 2017
CompletedStudy Start
First participant enrolled
September 14, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 24, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 24, 2020
CompletedFebruary 10, 2022
February 1, 2022
2.4 years
August 25, 2017
February 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions)
Measured by a kappa test
Day 0
Study Arms (2)
ABPA
EXPERIMENTAL15 patients with ABPA
Severe asthma
ACTIVE COMPARATOR12 patients with severe asthma
Interventions
It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Eligibility Criteria
You may qualify if:
- study patients have a diagnosis of ABPA
- control patients have severe asthma
- All the patients are ≥ 18 years old, have social security care, signature of consent form
You may not qualify if:
- cystic fibrosis
- other type of aspergilloses
- contraindication for MRI
- woman without effective contraception
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Bordeaux
Pessac, 33604, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Julie MACEY, MD
University Hospital, Bordeaux
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2017
First Posted
August 29, 2017
Study Start
September 14, 2017
Primary Completion
January 24, 2020
Study Completion
January 24, 2020
Last Updated
February 10, 2022
Record last verified: 2022-02